An interventional study of NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation and Carbon orthosis (control) in Stroke, Multiple Sclerosis and Cerebral Palsy, sponsored by ÖSSUR France. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by ÖSSUR France (part of Embla Medical hf.) · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Stroke with a site in France — 141 open to participants now, 160 under way, 12 of them phase 3. Stroke · France.
Among the 543 studies in Stroke with a site in France, this one is the 252nd largest by planned enrollment of the 368 interventional ones that give a count, is one of 39 that started in 2025, is one of 275 with no phase, reaches primary completion later than 54 of the 159 other live ones, and was the 503rd registered.
8,258 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →141 of the 543 studies in Stroke with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 52 · Phase 4 17
First in 1998; this study’s year is marked. 39 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 49 across 6,036 interventional studies indexed under Stroke.
Median enrollment 65 across the 368 interventional studies, 180 across the 173 observational. Of the 331 that completed or were terminated, 30 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 543 have an industry lead sponsor. The 10 most frequent:
This study is registered under ÖSSUR France, one of the names counted as Embla Medical hf.. Under that name alone:
This is the only study on the registry with ÖSSUR France as lead sponsor.
Embla Medical hf. has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
49 of the studies in Stroke with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03998852Phase 3University Hospital, BordeauxIn Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. | 2027-04-13 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT00759304Centre Hospitalier Universitaire de Saint EtienneEvaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 543 studies in Stroke with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this randomized, cross-over, multi-center, intention-to-treat, open-label study study is to determine the benefits of the NEUROSWING device on gait speed in patients with dorsal and/or plantar flexor deficits, compared with the use of a carbon orthosis. Each patient will benefit in random order from a 14-day investigation period with the NEUROSWING device and a 14-day control period with a carbon orthosis. These two 2-week periods will be separated by one week, during which no orthosis will be worn and no evaluation will be carried out. Patients will be randomized to determine which phase they will start with. The primary endpoint is walking speed, which will be measured by comparing the results of the 10-meter walk test. For the secondary endpoints, patients will be assessed using the Functional Gait Assessment (FGA), the 6-minute test and an analysis system that will analyze other gait parameters (duration of the different phases of the gait cycle, cadence and step length). In order to carry out the assessments, each patient included will have 12 visits spread over 5 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Deficit of the dorsal and/or plantar flexors with at least one of the following components specific to the indication of an AFO:
Exclusion Criteria:
Condition A corresponds to the control phase where the patient will use the control device during 14 days.
Device: Carbon orthosis (control)
Condition B corresponds to the experimental phase where the patient will use the experimental device during 14 days.
Device: NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation
The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : * Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days * Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days
The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : * Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days * Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days
Walking speed : 10m walk test
Time frame: At all 12 visits from baseline (day 1), to end of study (day 35)
Functional Gait Assessment (FGA)
The Functional Gait Assessment (FGA) is a modification of the Dynamic Gait Index (DGI) that uses higher-level tasks to increase the applicability of the test to people with vestibular disorders and to eliminate the ceiling effect of the original test. Three items were added to the DGI because these were noted to be difficult in people with vestibular disorders. The FGA is used to assess postural stability during various walking tasks : * Gait on a Level Surface * Change in Gait Speed * Gait with Horizontal Head Turns * Gait with Vertical Head Turns * Gait and Pivot Turn * Step Over Obstacle * Gait with Narrow Base of Support * Gait with Eyes Closed * Ambulating Backwards * Steps
Time frame: At baseline (day 1), day 14, day 22 and end of study (day 35)
6 minute walk test
Time frame: At baseline (day 1), day 14, day 22 and end of study (day 35)
Spatio-temoral gait analysis
Time frame: At baseline (day 1), day 14, day 22 and end of study (day 35)
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.
Of 144 industry-sponsored interventional studies with no phase under Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 14 months is below that.
Counting every sponsor, half of 3,261 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Jul 2025 → Oct 2025, primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.